0000000000766685

AUTHOR

Valdis Pirags

0000-0002-3650-7394

showing 39 related works from this author

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct

Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue

2020

The most common type of pituitary neoplasms is benign pituitary adenoma (PA). Clinically significant PAs affect around 0.1% of the population. Currently, there is no established human PA cell culture available and when PA tumor cells are cultured they form two distinct types depending on culturing conditions either free-floating aggregates also known as pituispheres or cells adhering to the surface of cell plates and displaying mesenchymal stem-like properties. The aim of this study was to trace the origin of sphere-forming and adherent pituitary cell cultures and characterize the potential use of these surgery derived cell lines as PA model. We carried out a paired-end exome sequencing of …

AdenomaAdult0301 basic medicinetumor sequencingSomatic cellEndocrinology Diabetes and MetabolismPopulationCell030209 endocrinology & metabolismpituitary adenomaPituitary neoplasmBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGermlinewhole exome sequencing03 medical and health sciences0302 clinical medicineEndocrinologyBiomarkers TumorTumor Cells CulturedmedicineHumansExomePituitary NeoplasmseducationExome sequencingOriginal Researcheducation.field_of_studylcsh:RC648-665Mesenchymal stem cellpituitary adenoma culturesMiddle AgedPrognosisMolecular biologyGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureCell culturePituitary GlandMutationpituispheresFollow-Up StudiesFrontiers in Endocrinology
researchProduct

Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients

2013

Abstract Aims The present study was undertaken to investigate the relationship between glyoxalase 1 (Glo1) enzyme activity and painful diabetic neuropathy (DN) in patients with diabetes mellitus. Methods Glo1 activity and biochemical markers were determined in blood samples from 108 patients with type 1 diabetes, 109 patients with type 2 diabetes, and 132 individuals without diabetes as a control. Painful and painless peripheral DN was assessed and multivariate regression analysis was used to determine independent association of Glo1 activity with occurrence of painful DN. Results In patients with type 1 and type 2 diabetes mellitus and painful DN compared to patients with painless DN, Glo1…

AdultMalemedicine.medical_specialtyMultivariate analysisEndocrinology Diabetes and MetabolismPainType 2 diabetesSeverity of Illness IndexGastroenterologyEndocrinologyDiabetic NeuropathiesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansPain MeasurementGlycated HemoglobinType 1 diabetesbusiness.industryConfoundingLactoylglutathione LyasePeripheral Nervous System DiseasesType 2 Diabetes MellitusMiddle Agedmedicine.diseasePeripheralDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2Painful diabetic neuropathyDisease ProgressionFemalebusinessBiomarkersJournal of Diabetes and its Complications
researchProduct

Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue

2021

Acromegaly is a disease mainly caused by pituitary neuroendocrine tumor (PitNET) overproducing growth hormone. First-line medication for this condition is the use of somatostatin analogs (SSAs), that decrease tumor mass and induce antiproliferative effects on PitNET cells. Dopamine agonists (DAs) can also be used if SSA treatment is not effective. This study aimed to determine differences in transcriptome signatures induced by SSA/DA therapy in PitNET tissue. We selected tumor tissue from twelve patients with somatotropinomas, with half of the patients receiving SSA/DA treatment before surgery and the other half treatment naive. Transcriptome sequencing was then carried out to identify diff…

Cancer Researchbusiness.industrysomatostatin/dopamine (SSA/DA) therapynext generation sequencing (NGS)medicine.disease_causemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TranscriptomeExtracellular matrixSomatostatinOncologyDownregulation and upregulationDopamineGene expressionAcromegalyCancer researchMedicineacromegalysomatotropinomabusinessCarcinogenesistranscriptomeOriginal Researchmedicine.drugFrontiers in Oncology
researchProduct

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

2016

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear(1). Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (P = 6.6 x 10(-14)) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry. rs8192675 was the top cis expression quantitative trait locus (cis-eQTL) for SLC2A2 in 1,226 human liver samples, suggesting a key role …

Blood Glucose0301 basic medicinemedicine.medical_specialtyendocrine system diseasesGenome-wide association studyType 2 diabetesPolymorphism Single NucleotideWhite PeopleBody Mass Index03 medical and health sciencesQuantitative Trait HeritableInternal medicineDiabetes mellitusGeneticsmedicineHumansHypoglycemic AgentsAlleleGlycemicGlucose Transporter Type 2Glycated HemoglobinbiologyGlucose transporternutritional and metabolic diseasesmedicine.diseaseMetformin3. Good healthMetformin030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2biology.proteinGLUT2Genome-Wide Association Studymedicine.drug
researchProduct

Association of microsatellite polymorphisms of the human 14q13.2 region with type 2 diabetes mellitus in Latvian and Finnish populations.

2007

A polymorphic microsatellite in intron 6 of the human proteasome core particle PSMA6 gene (HSMS006), and four other microsatellites localized upstream on human chromosome 14q13.2 (HSMS801, HSMS702, HSMS701, HSMS602), were genotyped in 104 type 2 diabetic patients and 129 age-matched control subjects from Latvia and replicated in 91 type 2 diabetic patients and 88 age-matched healthy control subjects from the Botnia Study in Finland. In type 2 diabetic patients from both populations the HSMS006 (TG)22 allele was two times more frequent compared to the control group. In the Latvian population the (CAA)8 allele of the HSMS602 marker was less frequent in the diabetic group, as was the (AC)24 al…

AdultMaleProteasome Endopeptidase ComplexPopulationPSMA6Type 2 diabetesBiologyGene FrequencyPolymorphism (computer science)Multienzyme ComplexesGeneticsmedicineHumansAlleleeducationAllele frequencyGenetics (clinical)AllelesFinlandAgedGeneticsChromosomes Human Pair 14education.field_of_studyPolymorphism GeneticType 2 Diabetes MellitusMiddle Agedmedicine.diseaseLatviaDiabetes Mellitus Type 2Case-Control StudiesMicrosatelliteFemaleMicrosatellite RepeatsAnnals of human genetics
researchProduct

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.

2021

Digital

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodErectile DysfunctionlawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicineRisk factorAgedbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasePrognosisImmunoglobulin Fc FragmentsErectile dysfunctionDiabetes Mellitus Type 2Cardiovascular DiseasesDulaglutideFemalebusinessBiomarkersmedicine.drugFollow-Up StudiesThe lancet. Diabetesendocrinology
researchProduct

P2-290 Socioeconomic status and mortality among people with diabetes mellitus in Latvia

2011

Introduction The chronic course of the disease and regular need for healthcare suggests that people with diabetes mellitus might be more affected by the socioeconomic inequalities in health. We assessed whether socioeconomic differences exist in mortality of diabetes patients in Latvia. Methods The study population consisted of 4179 diabetes patients (1339 men and 2840 women) participating in the Latvian diabetes survey in 2000. All deaths (n=1771) during a subsequent ten-year period and causes of death were identified through the Causes of Death Data Base. The Cox model was used to test associations (HR (95% CI) presented) between education, income and residence (rural/urban) and mortality…

GerontologyEpidemiologyProportional hazards modelbusiness.industryPublic Health Environmental and Occupational HealthDiseasemedicine.diseaseBlood pressureDiabetes mellitusmedicinePopulation studyHealth educationResidencebusinessSocioeconomic statusDemographyJournal of Epidemiology & Community Health
researchProduct

Identification of glyoxalase 1 polymorphisms associated with enzyme activity.

2013

The glyoxalase system and its main enzyme, glyoxalase 1 (GLO1), protect cells from advanced glycation end products (AGEs), such as methylglyoxal (MG) and other reactive dicarbonyls, the formation of which is increased in diabetes patients as a result of excessive glycolysis. MG is partly responsible for harmful protein alterations in living cells, notably in neurons, leading to their dysfunction, and recent studies have shown a negative correlation between GLO1 expression and tissue damage. Neuronal dysfunction is a common diabetes complication due to elevated blood sugar levels, leading to high levels of AGEs. The aim of our study was to determine whether single nucleotide polymorphisms (S…

AdultMalemedicine.medical_specialtyGenotypeType 2 diabetesPolymorphism Single Nucleotidechemistry.chemical_compoundEnzyme activatorLactoylglutathione lyaseInternal medicineDiabetes mellitusGeneticsmedicineHumansAllelesGeneticsType 1 diabetesbiologyMethylglyoxalLactoylglutathione LyaseGeneral MedicineMiddle Agedmedicine.diseaseEnzyme assayEnzyme ActivationEndocrinologyDiabetes Mellitus Type 1chemistryDiabetes Mellitus Type 2biology.proteinFemaleGlyoxalase systemGene
researchProduct

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

2011

OBJECTIVE To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. RESEARCH DESIGN AND METHODS The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone. RESULTS Following median (interquartile range) 71 (63–86) days drug withdrawal, overall glycemic status remained modestly improved in t…

RamiprilAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyPlaceboRosiglitazone03 medical and health sciencesDrug withdrawal0302 clinical medicineRamiprilInterquartile rangeInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsGlycemicOriginal ResearchAdvanced and Specialized Nursingbusiness.industryIncidence (epidemiology)IncidenceClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.disease3. Good healthSurgerySubstance Withdrawal SyndromeTreatment OutcomeDiabetes Mellitus Type 2FemaleThiazolidinedionesRosiglitazonebusinessmedicine.drugFollow-Up StudiesDiabetes Care
researchProduct

Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diab…

2020

Aims: To investigate the association between depressive symptomatology and health markers in type 1 diabetes. Methods: Four countries from the InterDiane Consortium had adopted the Finnish Diabetic Nephropathy Study protocol, including the Beck Depression Inventory (BDI). Associations between depression symptomatology, diabetes complications (diabetic nephropathy, proliferative retinopathy, major adverse cardiovascular events [MACE]) and vascular risk factors (metabolic syndrome, body mass index, glycaemic control) were investigated. Results: In a sample of 1046 participants (Croatia n = 99; Finland n = 314; Latvia n = 315; Lithuania n = 318), 13.4% displayed symptoms of depression (BDI sco…

MaleEndocrinology Diabetes and MetabolismDISEASEDiabetic nephropathy0302 clinical medicineEndocrinologyRisk FactorsGLYCEMIC CONTROLSurveys and QuestionnairesPrevalence030212 general & internal medicineDepression (differential diagnoses)2. Zero hungerDepressionGeneral MedicineMiddle AgedMetabolic syndrome3. Good healthEuropeType 1 diabetesFemaleHEALTHAdultmedicine.medical_specialty030209 endocrinology & metabolismRETINOPATHYDiabetes Complications03 medical and health sciencesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansVascular DiseasesType 1 diabetesbusiness.industry616.379-008.64 [udc]Beck Depression InventoryADULTSCAREmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 13121 General medicine internal medicine and other clinical medicineDepression ; Diabetes complications ; Metabolic syndrome ; Type 1 diabetesDiabetes mellitus type 1 ; psychology ; Depression ; Diabetes complications ; Metabolic syndrome ; Cross-sectional studiesSelf ReportMetabolic syndromebusinessBody mass indexMace
researchProduct

Erratum to: Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

Pediatricsmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInternal MedicinemedicineType 2 diabetesErratummedicine.diseasebusinessDiabetologia
researchProduct

Polymorphisms in FTO and near TMEM18 associate with type 2 diabetes and predispose to younger age at diagnosis of diabetes

2013

Variations in the FTO gene and near the TMEM18 gene are risk factors for common form of obesity, but have also been linked with type 2 diabetes (T2D). Our aim was to investigate the contribution of these variants to risk of T2D in a population in Latvia. Four single nucleotide polymorphisms (SNP) in the first and fourth intronic regions of FTO and one close to TMEM18 were genotyped in 987 patients with T2D and 1080 controls selected from the Latvian Genome Data Base (LGDB). We confirmed association of SNPs in the first intron (rs11642015, rs62048402 and rs9939609) of FTO and rs7561317 representing the TMEM18 locus with T2D. Association between SNP in FTO and T2D remained significant after c…

Linkage disequilibriumendocrine system diseasesPopulationAlpha-Ketoglutarate-Dependent Dioxygenase FTOSingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologyPolymorphism Single NucleotideFTO geneGeneticsmedicineHumansSNPAge of OnseteducationGeneticseducation.field_of_studyAge FactorsMembrane ProteinsProteinsnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseObesityDiabetes Mellitus Type 2Gene
researchProduct

Interleukin-6 gene promoter –174G/C polymorphism and insulin resistance: a pilot study

2007

Background: The aim of this pilot study was to evaluate the relationship between interleukin-6 promoter -174G/C (IL-6 -174G/C) polymorphism and insulin resistance (IR) in obese patients with coronary heart disease (CHD). Methods: Twenty obese male patients with CHD were selected from a larger database of patients (n=606). IL-6 -174G/C genotype was previously analysed and only homozygotes with the CC genotype (n=10) or GG genotype (n=10) were selected. IR was measured using the homeostasis model assessment for IR (HOMA-IR) method. Results: Differences in age, body mass index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), triglyceride (T…

Malemedicine.medical_specialtyGenotypemedicine.medical_treatmentClinical BiochemistryCoronary DiseasePilot ProjectsBiologychemistry.chemical_compoundInsulin resistanceRisk FactorsPolymorphism (computer science)Internal medicineGenotypemedicineHumansObesityPromoter Regions GeneticPancreatic hormoneAgedPolymorphism GeneticTriglycerideInterleukin-6InsulinCholesterol HDLBiochemistry (medical)Age Factorsnutritional and metabolic diseasesGeneral MedicineMiddle Agedmedicine.diseaseObesityEndocrinologychemistryCardiovascular DiseasesFemaleInsulin ResistanceBody mass indexClinical Chemical Laboratory Medicine
researchProduct

Standardized Map of Iodine Status in Europe

2020

Background: Knowledge about the population's iodine status is important, because it allows adjustment of iodine supply and prevention of iodine deficiency. The validity and comparability of iodine-related population studies can be improved by standardization, which was one of the goals of the EUthyroid project. The aim of this study was to establish the first standardized map of iodine status in Europe by using standardized urinary iodine concentration (UIC) data. Materials and Methods: We established a gold-standard laboratory in Helsinki measuring UIC by inductively coupled plasma mass spectrometry. A total of 40 studies from 23 European countries provided 75 urine samples covering the wh…

MaleEndocrinology Diabetes and MetabolismPopulationchemistry.chemical_elementNutritional Status030209 endocrinology & metabolismIodineMedical and Health SciencesMass Spectrometry03 medical and health sciencesYoung Adult0302 clinical medicineEndocrinologyPregnancyEnvironmental healthepidemiology ; iodine ; iodine supply ; method comparisonmedicineHumanseducationChildFinlandeducation.field_of_studyiodine; iodine supply; epidemiology; method comparisonGeographybusiness.industryiodineiodine supplyReproducibility of Resultsmedicine.diseaseIodine deficiencyEuropechemistryMethod comparisonmethod comparison030220 oncology & carcinogenesisFood FortifiedLinear ModelsRegression AnalysisepidemiologyFemalePregnant WomenClinical MedicinebusinessAlgorithmsIodine
researchProduct

Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

2019

Objective: Circulating free DNA (cfDNA) in general and circulating tumor DNA (ctDNA) in particular is becoming an increasingly used form of liquid biopsy biomarkers. In this study, we are investigating the ability to detect ctDNA from the plasma of pituitary adenoma (PA) patients. Design: Tumor tissue samples were obtained from planed PA resections, before which blood plasma samples were taken. Somatic variants found in PA tissue samples were evaluated in related cfDNA, isolated from plasma samples. Methods: Sanger sequencing, as well as previously obtained whole-exome sequencing data, were used to evaluate somatic variants composition in tumor tissue samples. cfDNA was isolated from the sa…

0301 basic medicineSomatic cellEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpituitary adenomaBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyDNA sequencing03 medical and health sciencessymbols.namesakeGNAS0302 clinical medicineEndocrinologyBlood plasmaTaqManGNAS complex locusLiquid biopsyOriginal ResearchSanger sequencingcirculating tumor DNAlcsh:RC648-665AmpliconMolecular biology030104 developmental biologybiology.proteinsymbolsnext-generation sequencingcompetitive allele-specific TaqManFrontiers in Endocrinology
researchProduct

Nitric oxide metabolism is impaired by type 1 diabetes and diabetic nephropathy

2020

Diabetes leads to reduced nitric oxide bioavailability, resulting in endothelial dysfunction. However, overproduction of nitric oxide due to hyperglycaemia is associated with oxidative stress and tissue damage. The objective of this study was to characterise nitric oxide production (NO) and added nitrite and nitrate (NO(2)(-)+NO(3)(-)) concentration in the blood and urine of patients with and without diabetic nephropathy. A total of 268 patients with type 1 diabetes and 69 healthy subjects were included. Diabetic nephropathy was defined as macroalbuminuria and/or estimated glomerular filtration rate below 60 ml/min/1.73 cm(2). NO(2)(-)+NO(3)(-) concentration was measured by Griess reaction.…

inorganic chemicals0301 basic medicinemedicine.medical_specialtyRenal functionGeneral Biochemistry Genetics and Molecular BiologyNitric oxideNephropathyDiabetic nephropathyExcretion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDiabetes mellitusmedicineGeneral Pharmacology Toxicology and PharmaceuticsType 1 diabetesbusiness.industryGeneral NeuroscienceArticlesGeneral Medicinemedicine.disease030104 developmental biologyEndocrinologychemistry030220 oncology & carcinogenesisAlbuminuriamedicine.symptombusinessBiomedical Reports
researchProduct

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in di…

2013

The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C <70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction was numerically greater when switching to EZ/S vers…

MaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologySeverity of Illness IndexAtorvastatinLongitudinal StudiesRosuvastatin CalciumAged 80 and overeducation.field_of_studySulfonamidesAnticholesteremic AgentsMiddle AgedRosuvastatin CalciumDrug CombinationsCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleDrug MonitoringCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyStatinmedicine.drug_classPopulationHypercholesterolemiaUrologyDiabetes ComplicationsEzetimibeDouble-Blind MethodInternal MedicinemedicineHumansRosuvastatinPyrrolescardiovascular diseaseseducationAgedbusiness.industrynutritional and metabolic diseasesCholesterol LDLFluorobenzenesPyrimidinesSimvastatinHeptanoic AcidsAzetidinesEzetimibe/simvastatinbusinessDiabetic AngiopathiesDiabetesvascular disease research
researchProduct

Association of metformin administration with gut microbiome dysbiosis in healthy volunteers

2018

Background Metformin is a widely used first-line drug for treatment of type 2 diabetes. Despite its advantages, metformin has variable therapeutic effects, contraindications, and side effects. Here, for the very first time, we investigate the short-term effect of metformin on the composition of healthy human gut microbiota. Methods We used an exploratory longitudinal study design in which the first sample from an individual was the control for further samples. Eighteen healthy individuals were treated with metformin (2 × 850 mg) for 7 days. Stool samples were collected at three time points: prior to administration, 24 hours and 7 days after metformin administration. Taxonomic composition of…

0301 basic medicineMaleendocrine system diseasesPhysiologylcsh:MedicineType 2 diabetesGut floraPathology and Laboratory MedicineOpportunistic Pathogens0302 clinical medicineRNA Ribosomal 16SMedicine and Health SciencesLongitudinal Studieslcsh:ScienceData ManagementMultidisciplinarybiologydigestive oral and skin physiologyHigh-Throughput Nucleotide SequencingGenomicsHealthy VolunteersMetformin3. Good healthMetforminBacterial PathogensTolerabilityMedical MicrobiologyFemalePathogensmedicine.drugResearch ArticleMicrobial TaxonomyAdultDNA BacterialEscherichiaComputer and Information SciencesClostridiaceae030209 endocrinology & metabolismMicrobial GenomicsPlaceboDNA RibosomalMicrobiologyDrug Administration Schedule03 medical and health sciencesYoung AdultEnterobacteriaceaeAdverse ReactionsmedicineGeneticsHumansMicrobiomeMicrobial PathogensTaxonomyPharmacologyClostridiumBacteriabusiness.industryPeptostreptococcusTherapeutic effectlcsh:RGut BacteriaOrganismsBiology and Life SciencesSequence Analysis DNAmedicine.diseasebiology.organism_classificationGastrointestinal Microbiome030104 developmental biologyDysbiosislcsh:QMicrobiomebusinessDysbiosisPLOS ONE
researchProduct

Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response

2020

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naive volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholester…

0301 basic medicineMaleendocrine system diseasesMolecular biologyGene ExpressionType 2 diabetesPharmacologyBiochemistryTranscriptome0302 clinical medicineEndocrinologyMedical ConditionsSequencing techniquesGastrointestinal CancersBreast TumorsMedicine and Health SciencesHomeostasisEnergy-Producing OrganellesWhole bloodMultidisciplinarySmall nuclear RNABiguanideQRRNA sequencingGenomicsMiddle AgedMetforminMetforminMitochondriaType 2 DiabetesNucleic acidsCholesterolSmall nucleolar RNAOncology030220 oncology & carcinogenesisMedicineFemaleCellular Structures and OrganellesTranscriptome Analysismedicine.drugResearch Articlemedicine.drug_classEndocrine DisordersScienceGastroenterology and HepatologyBioenergetics03 medical and health sciencesBreast CancermedicineGeneticsDiabetes MellitusHumansNon-coding RNAGlycemicAgedbusiness.industryGene Expression ProfilingType 2 Diabetes Mellitusnutritional and metabolic diseasesBiology and Life SciencesComputational BiologyCancers and NeoplasmsCell Biologymedicine.diseaseGenome AnalysisGene regulationGene expression profilingResearch and analysis methods030104 developmental biologyMolecular biology techniquesMetabolic DisordersRNAbusinessBlood Chemical AnalysisPLoS ONE
researchProduct

Survey of autoantibody responses against tumor-associated antigens in thyroid cancer

2014

Background Autoantibodies against tumor-associated antigens (TAAs) have been shown to serve as highly specific serological biomarkers for the diagnosis of various solid cancers. Although the autoimmunity against thyroid tissue specific antigens has been studied extensively, so far, the autoantibody responses against common TAAs such as cancer-testis antigens (CTAs), mutated or differentiation antigens have not been comprehensively analyzed in patients with thyroid cancer. Objective The current study aims to characterize the frequency of autoantibody responses against common TAAs in patients with thyroid cancer and benign thyroid nodules. Methods A phage-displayed antigen microarray comprisi…

AdultMaleThyroid nodulesendocrine systemCancer ResearchLung Neoplasmsendocrine system diseasesBreast NeoplasmsYoung AdultBreast cancerAntigenAntigens NeoplasmBiomarkers TumorGeneticsmedicineHumansThyroid NeoplasmsLung cancerMelanomaThyroid cancerAgedAutoantibodiesAged 80 and overbusiness.industryThyroidAutoantibodyGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureOncologyCase-Control StudiesImmunologyCancer/testis antigensFemalebusinessCancer Biomarkers
researchProduct

Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients

2020

BackgroundThe study was conducted to investigate the effects of metformin treatment on the human gut microbiome's taxonomic and functional profile in the Latvian population, and to evaluate the correlation of these changes with therapeutic efficacy and tolerance.MethodsIn this longitudinal observational study, stool samples for shotgun metagenomic sequencing-based analysis were collected in two cohorts. The first cohort included 35 healthy nondiabetic individuals (metformin dose 2x850mg/day) at three time-points during metformin administration. The second cohort was composed of 50 newly-diagnosed type 2 diabetes patients (metformin dose-determined by an endocrinologist) at two concordant ti…

AdultMale0301 basic medicinemedicine.medical_specialtyendocrine system diseasesSciencePopulationPrevotella030209 endocrinology & metabolismType 2 diabetesGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineLongitudinal StudiesMicrobiomeeducationeducation.field_of_studyMultidisciplinarybiologyBacteroidetesbusiness.industryMicrobiotaQTherapeutic effectRnutritional and metabolic diseasesmedicine.diseasebiology.organism_classificationMetforminGastrointestinal MicrobiomeMetforminLactococcus lactis030104 developmental biologyDiabetes Mellitus Type 2CohortMedicineDialisterFemalebusinessResearch Articlemedicine.drugEnterococcus faeciumPLOS ONE
researchProduct

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

2020

Digital

AdultMalemedicine.medical_specialtyRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansHypoglycemic AgentsCognitive DysfunctionRisk factorAgedbusiness.industryHazard ratioMontreal Cognitive AssessmentMiddle Agedmedicine.diseaseImmunoglobulin Fc FragmentsTreatment OutcomeDiabetes Mellitus Type 2Digit symbol substitution testFemaleDulaglutideNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Angiopoietin 2 and Neuropeptide Y are Associated with Diabetic Kidney Disease in Type 1 Diabetes Mellitus

2020

Abstract Background Serum angiopoietin 2 levels have been associated with endothelial dysfunction and diabetic kidney disease. Derangements in autonomous nervous system lead to increased production of vasoconstrictory and angiogenic mediators such as norepinephrine and neuropeptide Y and are associated with increased risk of microvascular complications. Aim To investigate associations between angiopoietin 2, neuropeptide Y and diabetic kidney disease in patients with type 1 diabetes mellitus. Methods 289 patients with type 1 diabetes mellitus duration > 1 year were included. Patients were stratified according to presence of diabetic nephropathy (macroalbuminuria, estimated glomerular fil…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRenal functionDiseaseAngiopoietin-2Norepinephrine (medication)Diabetic nephropathyEndocrinologyInternal medicineInternal MedicinemedicineHumansDiabetic NephropathiesNeuropeptide YEndothelial dysfunctionType 1 diabetesbusiness.industryGeneral MedicineStepwise regressionmedicine.diseaseNeuropeptide Y receptorDiabetes Mellitus Type 1EndocrinologyHypertensionFemalebusinessBiomarkersGlomerular Filtration Ratemedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Impact of interval walking training managed through smart mobile devices on albuminuria and leptin/adiponectin ratio in patients with type 2 diabetes

2020

Abstract Background Interval walking training has demonstrated more pronounced positive effects on physical fitness and metabolism in type 2 diabetes (T2D), compared to continuous walking. One of the pathogenic mechanisms of T2D is associated with derangements in leptin/adiponectin axis, which might predispose affected individuals to vascular inflammation and albuminuria. The aim of this study was to investigate the effects of interval walking training delivered through smart mobile devices upon albuminuria and leptin/adiponectin ratio in patients with T2D. Methods Patients with T2D aged 35–75 were randomized into control (n = 26) and interval training (IT, n = 14) groups. Patients in IT gr…

AdultLeptinMalemedicine.medical_specialtyendocrine system diseasesPhysiologyPhysical fitnessWalkingType 2 diabetes030204 cardiovascular system & hematologylcsh:PhysiologyalbuminuriaInterval training03 medical and health sciences0302 clinical medicineleptin/adiponectin ratioPhysiology (medical)Internal medicineDiabetes mellitusinterval walkingHumansMedicineAgedlcsh:QP1-981diabetesAdiponectinbusiness.industryLeptinnutritional and metabolic diseasesOriginal Articlesmobile applicationMiddle Agedmedicine.diseaseMobile ApplicationsObesityExercise TherapyDiabetes Mellitus Type 2AlbuminuriaCardiologyOriginal ArticleFemaleAdiponectinSmartphonemedicine.symptombusinesshuman activitieshormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryPhysiological Reports
researchProduct

Stronger Association of Common Variants in TCF7L2 Gene with Nonobese Type 2 Diabetes in the Latvian Population

2012

Polymorphisms in the gene coding for transcription factor 7 like 2 (TCF7L2) are recognized as the strongest common genetic risk factors for type 2 diabetes (T2D) across multiple ethnicities. This study was conducted to evaluate an association between TCF7L2 variants and diabetes susceptibility in the population of Latvia. We genotyped 4 single nucleotide polymorphisms (SNP) rs7901695, rs7903146, rs11196205 and rs12255372 in 1 093 controls and 1 043 diabetic subjects. Association with T2D was found for 3 SNPs rs7901695, rs7903146 and rs12255372 in the whole sample (under an additive genetic model, the adjusted odds ratios (OR) were 1.26, 95% CI [1.08-1.48], P=0.003; OR=1.32, 95% CI [1.12-1.5…

Maleendocrine systemendocrine system diseasesEndocrinology Diabetes and MetabolismPopulationSingle-nucleotide polymorphismType 2 diabetesBiologyPolymorphism Single NucleotideBody Mass IndexEndocrinologyPolymorphism (computer science)Databases GeneticGenetic modelInternal MedicinemedicineHumansSNPGenetic Predisposition to DiseaseObesityeducationGenetic Association StudiesGeneticseducation.field_of_studynutritional and metabolic diseasesGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLatviaDiabetes Mellitus Type 2Case-Control StudiesFemaleTranscription Factor 7-Like 2 ProteinTCF7L2Experimental and Clinical Endocrinology & Diabetes
researchProduct

587 VASOMOTOR DYSFUNCTION AND ALTERATIONS OF CIRCULATING CYTOKINES IN DIABETIC POLYNEUROPATHY PATIENTS WITH AND WITHOUT MECHANICAL ALLODYNIA

2009

medicine.medical_specialtyAnesthesiology and Pain MedicineDiabetic polyneuropathybusiness.industryInternal medicineCardiologymedicineVasomotor dysfunctionbusinessMechanical AllodyniaEuropean Journal of Pain
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial…

2017

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is…

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologymedicine.diseaseClinical trial03 medical and health sciences0302 clinical medicineEndocrinologyBlood pressureDiabetes mellitusInternal medicineHeart failureInternal MedicinemedicinePhysical therapyDulaglutideMyocardial infarctionbusinessStrokemedicine.drugDiabetes, Obesity and Metabolism
researchProduct

Pepsinogen Test for the Evaluation of Precancerous Changes in Gastric Mucosa: a Population-Based Study

2018

Aims: The aim of the study was to evaluate the rationale of blood pepsinogen (PG) testing in population based screening settings.Methods: Participants from a cross-sectional population-based study of cardiovascular risk factors in Latvia were invited to participate in the current study. Pepsinogen I and II were measured in blood samples taken during the initial study and at follow-up; upper gastrointestinal endoscopy was performed. There were three groups of patients: with moderately decreased (PG I< 70 ng/ml and PG I/PG II ratio < 3), with strongly decreased (PG I< 30 ng/ml and PG I/PG II ratio < 2), and with normal PG level. Biopsy with H. pylori detection was performed (updat…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyEndoscopy GastrointestinalHelicobacter Infections03 medical and health sciences0302 clinical medicinePepsinStomach NeoplasmsPepsinogen AInternal medicine0502 economics and businessBiopsyPepsinogen CGastric mucosamedicineHumansMass ScreeningeducationMass screeningAgededucation.field_of_studyHelicobacter pyloribiologymedicine.diagnostic_testbusiness.industryStomach05 social sciencesGastroenterologyCancerMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseasemedicine.anatomical_structureDysplasiaElder Nutritional Physiological PhenomenaGastritisbiology.proteinFemale050211 marketing030211 gastroenterology & hepatologyAtrophybusinessJournal of Gastrointestinal and Liver Diseases
researchProduct

Nitric Oxide Production and Arachidonic Acid Metabolism in Platelet Membranes of Coronary Heart Disease Patients with and without Diabetes

2001

<i>Aim:</i> To evaluate the levels of nitrite (NO<sup>–</sup><sub>2</sub>) and nitrate (NO<sup>–</sup><sub>3</sub>) ions and the incorporation of [<sup>3</sup>H]arachidonic acid (AA) into phospholipids of platelet membranes from coronary artery disease (CAD) patients with and without diabetes (NIDDM). <i>Subjects and Methods:</i> Eighteen CAD patients (group A), 18 CAD patients with NIDDM (group B), and 20 healthy controls (group C) without dyslipidemia, peripheral vascular disease and hypertension were included in the study. The groups were matched for age, sex and body mass index. The diagnosis of CAD was …

AdultBlood PlateletsMalemedicine.medical_specialtyCoronary Artery DiseaseNitric oxideCoronary artery diseasechemistry.chemical_compoundNitrateDiabetes mellitusInternal medicineHumansMedicinePlateletNitriteNitritesPhospholipidsAgedArachidonic AcidNitratesbusiness.industryCell MembraneGeneral MedicineMiddle AgedPlatelet Activationmedicine.diseaseMembraneEndocrinologyDiabetes Mellitus Type 2chemistrySpectrophotometryFemaleArachidonic acidbusinessMedical Principles and Practice
researchProduct

Seasonal Iodine Deficiency in Latvian School Children

2012

business.industryEndocrinology Diabetes and MetabolismLatvianmedicine.diseaseLatviaThyroid DiseasesIodine deficiencylanguage.human_languageEndocrinologyEnvironmental healthlanguagemedicineHumansSeasonsChildbusinessIodineThyroid
researchProduct

The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia

2014

OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any …

medicine.medical_specialty2902 Advanced and Specialized NursingEndocrinology Diabetes and Metabolismmedicine.medical_treatment10265 Clinic for Endocrinology and Diabetology610 Medicine & healthContext (language use)law.inventionRandomized controlled triallawInternal medicineDiabetes mellitusInternal MedicinemedicineAdvanced and Specialized NursingCancer preventionInsulin glarginebusiness.industryInsulinCancermedicine.diseaseMetformin2712 Endocrinology Diabetes and MetabolismEndocrinology2724 Internal MedicineNEOPLASIASbusinessmedicine.drugDiabetes Care
researchProduct

Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.

2012

Helicobacter pylori infection and atrophic gastritis are related to an increased risk for gastric cancer. There is a decrease in global H. pylori prevalence. We analyzed the prevalence of H. pylori infection in Latvia by the plasma IgG test and the presence of atrophy by means of pepsinogen testing.This subanalysis was carried out on a randomly selected cross-sectional sample of a general population of adults to access cardiovascular risk factors. Plasma samples were screened for H. pylori IgG (cutoff value 24 U/ml), and pepsinogens (Pg) I and II. Pg cutoff values of PgI/PgII ≤ 3 and PgI ≤ 70 ng/ml were used to assess the prevalence of atrophy of any grade and PgI/PgII ≤ 2 and PgI ≤ 30 ng/m…

AdultGastritis AtrophicMalemedicine.medical_specialtyHelicobacter pylori infectionAdolescentCross-sectional studyAtrophic gastritisGastroenterologySeverity of Illness IndexHelicobacter InfectionsYoung AdultAtrophySex FactorsPredictive Value of TestsRisk FactorsStomach NeoplasmsInternal medicinePepsinogen AmedicinePepsinogen CPrevalenceHumansYoung adultAgedAged 80 and overChi-Square DistributionHepatologybiologyHelicobacter pyloribusiness.industryGastroenterologyAge FactorsCancerMiddle Agedbacterial infections and mycosesmedicine.diseaseAntibodies BacterialLatviaCross-Sectional Studiesbiology.proteinLinear ModelsFemaleGastritismedicine.symptomAntibodybusinessPrecancerous ConditionsBiomarkersEuropean journal of gastroenterologyhepatology
researchProduct

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

2013

Purpose: This post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese (BMI ≥30 kg/m 2 ) and non-obese (BMI <30 kg/m 2 ) diabetic subjects. Methods: This was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids was estimated. Results: In obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/ simvastatin vs doubling the baseline statin dose or switchi…

MaleSimvastatinApolipoprotein BEndocrinology Diabetes and MetabolismAtorvastatinClinical Biochemistrychemistry.chemical_compoundEndocrinologyAtorvastatinRosuvastatin CalciumSulfonamidesNutrition and DieteticsbiologyAnticholesteremic AgentsDiabetesMiddle AgedRosuvastatin CalciumTreatment OutcomeFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyRosuvastatinYoung AdultEzetimibeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansPyrrolesRosuvastatinObesitycardiovascular diseasesAgedApolipoproteins BBiochemistry medicalCholesterolbusiness.industryResearchBiochemistry (medical)Statinnutritional and metabolic diseasesCholesterol LDLEzetimibemedicine.diseasePeptide FragmentsFluorobenzenesDiabetes Mellitus Type 1PyrimidinesEndocrinologyDiabetes Mellitus Type 2chemistryHeptanoic AcidsSimvastatinbiology.proteinAzetidinesEzetimibe/simvastatinbusinessLipids in Health and Disease
researchProduct

Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients

2009

Although many studies have shown that the metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) both are associated with chronic inflammatory state and are risk factors for coronary artery disease (CAD), it is still unclear which condition is a more important contributor to the increased production of inflammatory chemokines. The purpose of this study was to assess monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels and their association with insulin resistance and adiponectin concentrations in CAD patients, who were categorized as having T2DM, MS, or neither.CAD male patients were categorized into three groups: 24 non-obese patients with T2DM (D), 24 obese pati…

AdultMalemedicine.medical_specialtyChemokineDecreased adiponectinCoronary Artery DiseaseCoronary artery diseaseInsulin resistanceRisk FactorsInternal medicineInternal MedicinemedicineHumansObesityChemokine CCL2AgedMetabolic SyndromeAdiponectinbiologybusiness.industryMonocyteInterleukin-8nutritional and metabolic diseasesType 2 Diabetes MellitusMiddle Agedmedicine.diseasemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2biology.proteinAdiponectinInsulin ResistanceMetabolic syndromebusinessBiomarkersEuropean Journal of Internal Medicine
researchProduct

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly.

2011

ObjectiveThe aim of this study was to characterize the genetic variance of somatostatin receptor 5 (SSTR5) and investigate the possible correlation of such variants with acromegaly risk and different disease characteristics.Design and methodsThe SSTR5 gene coding region and 2000 bp upstream region was sequenced in 48 patients with acromegaly and 96 control subjects. Further, three single nucleotide polymorphisms (SNPs) were analyzed in the same group of acromegaly patients and in an additional group of 475 age- and sex-matched controls.ResultsIn total, 19 SNPs were identified in the SSTR5 gene locus by direct sequencing. Three SNPs (rs34037914, rs169068, and rs642249) were significantly ass…

Malemedicine.medical_specialty:MEDICINE [Research Subject Categories]Endocrinology Diabetes and MetabolismSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideSomatostatin receptorEndocrinologyInternal medicineAcromegalyDatabases GeneticmedicineHumansReceptors SomatostatinAlleleeducationAllele frequencyAllelesAgededucation.field_of_studySomatostatin receptor-5Polymorphism GeneticSomatostatin receptorReverse Transcriptase Polymerase Chain ReactionHaplotypeGeneral MedicineOdds ratioDNAMiddle Agedmedicine.diseaseLatviaHormonesEndocrinologyTreatment OutcomeHaplotypesAcromegalyClinical StudyFemaleEuropean journal of endocrinology
researchProduct

Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping

2015

Background: Prevalence estimates for celiac disease (CD) depend on the method used. The role of deamidated gliadin peptide (DGP) and genetic testing in epidemiological studies and diagnostic settings of celiac disease (CD) has still to be established. Objectives: The objective of this article is to assess the prevalence of CD in Latvia by combining serological tests with DQ2.5/ DQ8 testing. Methods: A total of 1444 adults from a randomly selected cross-sectional general population sample were tested by ELISA for tTG IgA, DGP IgA and IgG antibodies (QUANTA Lite, Inova Diagnostics Inc). Samples with tTG IgA 20U were tested for EMA IgA by indirect immunofluorescence assay, and all specimens wi…

medicine.medical_specialty:MEDICINE [Research Subject Categories]Tissue transglutaminasePopulationSerologyChemiluminescent assaysEpidemiologyGenotypePrevalenceCeliac diseaseMedicineDQ2.5/8 genotypeeducationGenotypingGenetic testingeducation.field_of_studyDeamidated gliadin peptidemedicine.diagnostic_testbiologybusiness.industryTissue transglutaminaseGastroenterologynutritional and metabolic diseasesOriginal ArticlesOncologyImmunologybiology.proteinAntibodybusinessUnited European Gastroenterology Journal
researchProduct